Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1977 Oct 14;12(2):125-32.
doi: 10.1007/BF00645133.

Disposition of valproic acid in man

Disposition of valproic acid in man

R Gugler et al. Eur J Clin Pharmacol. .

Abstract

The pharmacokinetics of valproic acid (VPA) have been studied in 6 healthy subjects following a single 600 mg dose, and after multiple doses over 12 days (1200 mg daily) of enteric-coated sodium valproate. A time lag before absorption of 1 to 2 h was observed in each subject, and then absorption was rapid, peak concentrations being recorded 3 to 4 h after administration of the dose. The plasma level decline was biphasic with a terminal half-life of 15.9 +/- 2.6 h in the single dose and 17.3 +/- 3.0 h in the multiple dose experiments. There was no evidence of dose dependent kinetics or autoinduction. Total plasma clearance was 0.0064 +/- 0.0011 l/kg X h. The apparent volume of distribution was small at 0.15 +/- 0.2 l/kg. The mean steady state plasma concentration (Css) reached after 4 days was 81.3 +/- 13.0 microgram/ml. Css observed was lower than Css predicted (99.2 +/- 14.7 microgram/ml) from single dose kinetics (p less than 0.001). The difference was probably due to a reduction in plasma protein binding at higher concentrations. VPA concentration in saliva was between 0.4 and 4.5% of the total plasma concentration and was not equal to the concentration of unbound drug in plasma (6.7 +/- 0.8% unbound). 3.2% of the dose was excreted in urine as the parent drug and 21.2% as conjugated metabolites.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Clin Pharmacol. 1975 Jun 13;8(5):337-41 - PubMed
    1. Br Med J. 1975 Nov 1;4(5991):255-6 - PubMed
    1. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):429-32 - PubMed
    1. N Engl J Med. 1971 Jul 29;285(5):264-7 - PubMed
    1. Clin Pharmacol Ther. 1974 Dec;16(6):1052-8 - PubMed

LinkOut - more resources